Dynavax Technologies Corp.

-0.72 (-3.82%)
Products, Regulatory

Clover Biopharmaceuticals Says Favorable Safety Profile In Spectra Trial

Published: 09/22/2021 11:29 GMT
Dynavax Technologies Corp. (DVAX) - Clover’s Covid-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 Spectra Trial Dominated by Variants of Concern and Interest.
Clover Biopharmaceuticals - Scb-2019 Achieved the Primary Efficacy Endpoint and Secondary Efficacy Endpoints in Spectra.
Clover Biopharmaceuticals - 100% Efficacy Against Severe Covid-19 & Hospitalization in Spectra Trial.
Clover Biopharmaceuticals - 84% Efficacy Against Moderate To-severe Covid-19 Caused by Any Strain of Sars-cov-2 in Spectra Trial.
Clover - Favorable Safety Profile in Spectra Trial; No Significant Differences in Systemic Adverse Events Or Severe/serious Adverse Events.
Clover - Plans to Make Submissions for Conditional Approval Applications to Regulatory Authorities (including China Nmpa, Ema and Who) in Q4 2021.
Clover - Plans to Commence Initial Product Launch of Scb-2019 (cpg 1018/alum) Potentially by the End of 2021.